Micro2Macr0
Macro Economist
SVRN's overdue audit leaves a Nasdaq delisting process a live risk. Per HAL, the October 27 exception deadline could lead to a delisting determination if audited financials are not filed; a hearing request buys time but guarantees nothing. Fugazi Research alleges Ernst & Young resigned when the NEAR treasury launched and the first three months of digital-asset activity had no auditor. SVRN is only worth considering for additions at daily gaps near $20 and $16. x.com x.comÂ
Netcapital's delayed-report notice and AI-asset acquisition headlines do not establish a fresh trigger for its pre-market surge. The move is a fade candidate, with squeeze risk at 7/10 and hard-to-borrow shares. x.comÂ
Nautilus Biotechnology remains too speculative and faces eventual Nasdaq delisting if it cannot hold above $1. A price floor just under $1 after its collapse looks technically supportive, and there are early signs of commercial interest, but it is still a wild card. x.comÂ
Dare Bioscience looks set for a run, with two products in its pipeline, and the current weakness looks like the final crunch. Having just completed an offering, it should not let a delisting happen despite a market cap of about $13M. x.com x.comÂ
Tenon Medical is one to avoid after a 12% jump on the full commercial launch of its SImmetry+ SI joint fusion screw. The stock carries high squeeze risk, is hard to borrow and faces delisting risk. x.comÂ
WM Technology is not worth buying even after its fall, because there are many better options. Some holders likely owned it only because it was Nasdaq-listed and compliant, and the illiquidity premium is hard to price. @_OuttaControl argues it already traded under 1x sales with no value assigned to the business, and @Moneyman_2017 warns trading will get weird on the OTC market. Even on a standalone view of cannabis and software it would be tempting, but it is a pass. x.com x.comÂ